Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
110 hedge funds and large institutions have $136M invested in Insys Therapeutics, Inc. in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 11 closing their positions.
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
44% more capital invested
Capital invested by funds: $94.2M → $136M (+$41.3M)
17% more call options, than puts
Call options by funds: $5.49M | Put options by funds: $4.68M
12% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 25
7% more funds holding
Funds holding: 103 → 110 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
+$1.75M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$955K |
| 4 |
Millennium Management
New York
|
+$949K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$803K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$3.85M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$652K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$477K |
| 4 |
Barclays
London,
United Kingdom
|
-$322K |
| 5 |
VF
Virtu Financial
New York
|
-$253K |
INSY Hedge Fund Activity: Q3 2018 in Review
110 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q3 2018, worth a combined $136M — up 44% from $94.2M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new INSY positions and 11 closed out — a net gain of 7 holders — while 28 added to existing stakes and 25 trimmed.
The largest buyer was Norges Bank, adding an estimated $1.75M. The largest seller was OrbiMed, cutting an estimated $3.85M.
- 110 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q3 2018, up from 103 in Q2 2018.
- Funds reported $136M of Insys Therapeutics, Inc. stock for Q3 2018, up 44% quarter-over-quarter.
- 18 funds opened new Insys Therapeutics, Inc. positions in Q3 2018 and 11 closed out, a net change of +7 holders.
- The largest Insys Therapeutics, Inc. buyer in Q3 2018 was Norges Bank, an estimated $1.75M added.
- The largest Insys Therapeutics, Inc. seller in Q3 2018 was OrbiMed, an estimated $3.85M sold.
Based on aggregated 13F filings for Q3 2018.